Seattle biotech's rare approach takes cancer fight to next level
May 28, 2014
Source - KING 5 TV
Medical research institutions may all target the same maladies, but they regularly compete with each other over talent and funding. So how unusual is it for three of the country's top cancer research facilities to combine their efforts to form a biotech startup company? "It is relatively rare to bring three institutions of that caliber together to collaborate rather than to compete," said Hans Bishop, CEO and co-founder of Juno Therapeutics. It's now his job to help build a business model for Juno, and commercialize the lab work that Fred Hutchinson Cancer Research Center, Seattle Children's Research Institute and New York's Memorial Sloan Kettering are pursuing in immunotherapy.